Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023)

Ovid Therapeutics filings provide 8 years of Other Operating Expenses readings, the most recent being -$1000.0 for Q1 2023.

  • Quarterly Other Operating Expenses fell 100.48% to -$1000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Dec 2023, down 100.13% year-over-year, with the annual reading at -$45690.0 for FY2021, 111.56% down from the prior year.
  • Other Operating Expenses hit -$1000.0 in Q1 2023 for Ovid Therapeutics, down from $836085.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $836085.0 in Q3 2022 and bottomed at -$438260.0 in Q4 2020.
  • Average Other Operating Expenses over 5 years is $109971.6, with a median of $3280.0 recorded in 2021.
  • The largest annual shift saw Other Operating Expenses surged 58195.11% in 2019 before it plummeted 11188.32% in 2022.
  • Ovid Therapeutics' Other Operating Expenses stood at $298720.0 in 2019, then crashed by 246.71% to -$438260.0 in 2020, then skyrocketed by 100.89% to $3903.0 in 2021, then skyrocketed by 21321.6% to $836085.0 in 2022, then crashed by 100.12% to -$1000.0 in 2023.
  • Per Business Quant, the three most recent readings for OVID's Other Operating Expenses are -$1000.0 (Q1 2023), $836085.0 (Q3 2022), and -$284127.0 (Q2 2022).